These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 3016128

  • 21. Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelet in whole blood.
    Saniabadi AR, Belch JJ, Lowe GD, Barbenel JC, Forbes CD.
    Haemostasis; 1987; 17(3):147-53. PubMed ID: 2440771
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Prostacyclin (PGI2) inhibits the development in human platelets of ADP and arachidonic acid-induced shape change and procoagulant activity.
    Ehrman ML, Jaffe EA.
    Prostaglandins; 1980 Dec; 20(6):1103-16. PubMed ID: 7010448
    [Abstract] [Full Text] [Related]

  • 24. The aggregation of isolated human platelets in the presence of lipoproteins and prostacyclin.
    Hassall DG, Owen JS, Bruckdorfer KR.
    Biochem J; 1983 Oct 15; 216(1):43-9. PubMed ID: 6360159
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Reduced platelet aggregation by effects of pentoxifylline on vascular prostacyclin isomerase and platelet cyclic AMP.
    Weithmann KU.
    Gen Pharmacol; 1983 Oct 15; 14(1):161-2. PubMed ID: 6298055
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effect of heparin on platelet aggregation inhibited by PGI2, trifluoperazine and verapamil.
    Weber DR, Nichols WK, Mohammad SF.
    Thromb Res; 1986 May 15; 42(4):477-87. PubMed ID: 3012821
    [Abstract] [Full Text] [Related]

  • 30. Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets.
    Kajikawa N, Nogimori K, Murata T, Nishio S, Uchiyama S.
    Arzneimittelforschung; 1989 Apr 15; 39(4):495-9. PubMed ID: 2665758
    [Abstract] [Full Text] [Related]

  • 31. Iloprost binding and inhibition of aggregation in platelet rich plasma. Differences between normal and type IIa hypercholesterolemic subjects.
    Oliva DW, Maderna P, Accomazzo MR, Nicosia S, Tremoli E.
    Biochem Pharmacol; 1989 Jan 01; 38(1):39-45. PubMed ID: 2462881
    [Abstract] [Full Text] [Related]

  • 32. Inhibition and subsequent enhancement of platelet responsiveness by prostacyclin in the rabbit. Relationship to platelet adenosine 3',5'-cyclic monophosphate.
    Vanderwel M, Haslam RJ.
    J Clin Invest; 1985 Jul 01; 76(1):233-40. PubMed ID: 2991338
    [Abstract] [Full Text] [Related]

  • 33. Platelet sensitivity to antiaggregatory prostaglandins (PGE1,D2,I2) in patients with peripheral vascular disease.
    Fitscha P, Kaliman J, Sinzinger H.
    Am J Hematol; 1985 May 01; 19(1):13-9. PubMed ID: 3885723
    [Abstract] [Full Text] [Related]

  • 34. Synergistic inhibition of platelet activation by plasmin and prostaglandin I2.
    Schafer AI, Zavoico GB, Loscalzo J, Maas AK.
    Blood; 1987 May 01; 69(5):1504-7. PubMed ID: 3032310
    [Abstract] [Full Text] [Related]

  • 35. Human plasma transforms prostacyclin (PGI2) into a platelet antiaggregatory substance which contracts isolated bovine coronary arteries.
    Gimeno MF, Sterin-Borda L, Borda ES, Lazzari MA, Gimeno AL.
    Prostaglandins; 1980 Jun 01; 19(6):907-16. PubMed ID: 6992238
    [Abstract] [Full Text] [Related]

  • 36. Platelet resistance to prostacyclin. Enhancement of the antiaggregatory effect of prostacyclin by pentoxifylline.
    Manrique RV, Manrique V.
    Angiology; 1987 Feb 01; 38(2 Pt 1):101-8. PubMed ID: 3030162
    [Abstract] [Full Text] [Related]

  • 37. Influence on platelet activity and red cell fluidity of epoprostenol and two stable prostacyclin analogues in vitro.
    Maurin N.
    Arzneimittelforschung; 1986 Aug 01; 36(8):1180-3. PubMed ID: 3096342
    [Abstract] [Full Text] [Related]

  • 38. Platelet zinc status regulates prostaglandin-induced signaling, altering thrombus formation.
    Coupland CA, Naylor-Adamson L, Booth Z, Price TW, Gil HM, Firth G, Avery M, Ahmed Y, Stasiuk GJ, Calaminus SDJ.
    J Thromb Haemost; 2023 Sep 01; 21(9):2545-2558. PubMed ID: 37210073
    [Abstract] [Full Text] [Related]

  • 39. The influence of age, sex, and the use of oral contraceptives on the inhibitory effects of endothelial cells and PGI2 (prostacyclin) on platelet function.
    Nordøy A, Svensson B, Haycraft D, Hoak JC, Wiebe D.
    Scand J Haematol; 1978 Sep 01; 21(3):177-87. PubMed ID: 362511
    [Abstract] [Full Text] [Related]

  • 40. Increased platelet malondialdehyde, but normal platelet sensitivity to adenosine-5-diphosphate and prostacyclin in well-controlled type 1 diabetics without vascular complications.
    Gisinger C, Schernthaner G.
    Diabetes Res; 1986 Oct 01; 3(8):401-5. PubMed ID: 3545622
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.